The 36-month beta value for CPHI is also noteworthy at 0.55. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.” The average price estimated by anal
/PRNewswire/ China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), a specialty pharmaceutical company, today announced.
China Pharma s (CPHI) Candesartan Hypertension Product Passes the Quality and Efficacy Consistency Evaluation of Generic Drugs streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
and a 36-month beta value of 0.46. Opinions on the stock are mixed, with 1 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.” The average price predicted for China Pharma Holdings Inc. (CPHI) by analysts is $45.00, The pub
In recent trading session, China Pharma Holdings Inc. (AMEX:CPHI) saw 0.25 million shares changing hands at last check today with its beta currently measuring 0.46. Company’s recent per share price level of $0.38 trading at $0.02 or 5.47% at last check today assigns it a market valuation of $3.45M